Condition
Age Related Maculopathy
Total Trials
5
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
20%
1 of 5 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (4)
Trial Status
Completed5
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT00494325CompletedPrimary
The Role of Macular Pigment in Patients With Age-related Macular Degeneration
NCT00746668Not ApplicableCompletedPrimary
A Multi-Center Study of Reading Rehabilitation in Macular Disease
NCT01648660Not ApplicableCompletedPrimary
Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation for Two More Years (LUTEGA 2)
NCT00763659Not ApplicableCompletedPrimary
Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation on Optical Density of AMD Patients (LUTEGA)
NCT00125632Not ApplicableCompletedPrimary
Measuring Reading Rehabilitation Outcomes
Showing all 5 trials